Merida Biosciences
Merida Biosciences raises $121M Series A at $500M valuation
Merida Biosciences: Series A Funding Round
Merida Biosciences has successfully raised $121M in Series A funding, reaching a valuation of $500M.
Company Overview
Developing therapeutics to eliminate pathogenic antibodies in autoimmune diseases
Funding Details
The Series A round was led by Bain Capital Life Sciences, with participation from Biotechnology Value Fund, Third Rock Ventures.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2024
- Employees: 40+
- Category: Biotech
Investment
Merida Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Bain Capital Life Sciences: Verified investor in Series A
- Biotechnology Value Fund: Verified investor in Series A
- Third Rock Ventures: Verified investor in Series A
Company Info
Investors (3)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free